Regenxbio Inc
RGNX7.760USD
-0.500-6.05%
終値 03/27, 16:00（ET）15分遅れの株価
196.72M時価総額
損失額直近12ヶ月PER
詳細情報 Regenxbio Inc 企業名
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Incの企業情報
企業コードRGNX
会社名Regenxbio Inc
上場日Sep 17, 2015
最高経営責任者「CEO」Simpson (Curran M)
従業員数353
証券種類Ordinary Share
決算期末Sep 17
本社所在地9804 Medical Center Drive
都市ROCKVILLE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号20850
電話番号12405528181
ウェブサイトhttps://regenxbio.com/
企業コードRGNX
上場日Sep 17, 2015
最高経営責任者「CEO」Simpson (Curran M)
Regenxbio Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+86.75%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+38.73%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+40.77%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+40.77%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+86.75%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+38.73%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+40.77%
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Mar 16
更新時刻: Mon, Mar 16
株主統計
種類
株主統計
株主統計
比率
Redmile Group, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.73%
The Vanguard Group, Inc.
6.54%
Fox (Allan Mark)
5.62%
JP Morgan Asset Management
4.91%
他の
66.74%
株主統計
株主統計
比率
Redmile Group, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.73%
The Vanguard Group, Inc.
6.54%
Fox (Allan Mark)
5.62%
JP Morgan Asset Management
4.91%
他の
66.74%
種類
株主統計
比率
Investment Advisor
31.72%
Investment Advisor/Hedge Fund
31.45%
Hedge Fund
8.34%
Individual Investor
8.12%
Research Firm
7.94%
Private Equity
0.97%
Corporation
0.53%
Family Office
0.36%
Bank and Trust
0.33%
他の
10.24%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
409
42.94M
84.82%
-6.24M
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Redmile Group, LLC
4.69M
9.27%
-82.33K
-1.72%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.16M
8.21%
-109.09K
-2.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.34M
6.59%
-83.09K
-2.43%
Sep 30, 2025
Fox (Allan Mark)
2.90M
5.73%
+7.77K
+0.27%
May 30, 2025
JP Morgan Asset Management
2.61M
5.16%
-375.24K
-12.57%
Sep 30, 2025
State Street Investment Management (US)
1.98M
3.92%
+141.23K
+7.66%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.45M
2.85%
+700.19K
+94.00%
Sep 30, 2025
Goldman Sachs & Company, Inc.
1.62M
3.2%
+15.37K
+0.96%
Sep 30, 2025
AQR Capital Management, LLC
1.29M
2.55%
+359.46K
+38.64%
Sep 30, 2025
Integral Health Asset Management, LLC
1.10M
2.17%
+400.00K
+57.14%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
WisdomTree BioRevolution Fund
2.25%
iShares Neuroscience and Healthcare ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Global X Genomics & Biotechnology ETF
0.65%
JPMorgan Fundamental Data Science Small Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.27%
State Street SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.08%
詳細を見る
WisdomTree BioRevolution Fund
比率2.25%
iShares Neuroscience and Healthcare ETF
比率1.02%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.85%
Global X Genomics & Biotechnology ETF
比率0.65%
JPMorgan Fundamental Data Science Small Core ETF
比率0.45%
ALPS Medical Breakthroughs ETF
比率0.27%
State Street SPDR S&P Biotech ETF
比率0.24%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.13%
Fidelity Enhanced Small Cap ETF
比率0.12%
ProShares Ultra Nasdaq Biotechnology
比率0.08%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
